表紙
市場調查報告書

全球乾癬治療藥市場分析:各治療等級(白細胞介素抑制劑、腫瘤壞死因子抑制劑)、治療類型(局部、全身、生物製藥) 2016年∼2022年

Psoriasis Drugs Market Analysis Report by Therapeutic Class (Interleukin-inhibitors, Tumor Necrosis Factor-inhibitors), by Treatment (Topicals, Systemic, Biologics), and Segment Forecasts, 2016 - 2022

出版商 Grand View Research, Inc. 商品編碼 582019
出版日期 內容資訊 英文 115 Pages
商品交期: 2-3個工作天內
價格
Back to Top
全球乾癬治療藥市場分析:各治療等級(白細胞介素抑制劑、腫瘤壞死因子抑制劑)、治療類型(局部、全身、生物製藥) 2016年∼2022年 Psoriasis Drugs Market Analysis Report by Therapeutic Class (Interleukin-inhibitors, Tumor Necrosis Factor-inhibitors), by Treatment (Topicals, Systemic, Biologics), and Segment Forecasts, 2016 - 2022
出版日期: 2018年09月21日內容資訊: 英文 115 Pages
簡介

全球乾癬治療藥市場在整個預測期內預計將以9.4%的年複合成長率發展,2022年前市場規模將成長到211億1,000萬美元。對疾病的認識度的提高,及生物製藥的償付制度的擴充等成為促進這個市場成長的主要原因。

本報告提供全球乾癬治療藥市場調查,市場概要,各疾病的流行病學,主要各地區的盛行率及罹患率的變化與預測,有前途的候補藥的開發平台,競爭情形,主要企業的簡介等全面性資訊。

目錄

第1章 調查方法

  • 資訊採購
  • 資訊分析

第2章 摘要整理

第3章 疾病的底層塗料和流行病學

  • 疾病的底層塗料
  • 流行病學:各適應症
  • 主要市場(美國,日本,歐盟5國)的盛行率(成果值)
  • 主要市場(美國,日本,歐盟5國)的罹患率(成果值)
  • 主要市場(美國,日本,歐盟5國)的罹患率(預測值)

第4章 市場概要

  • 簡介/市場概要
  • 專利到期
  • 成長要素與課題
  • 交易情勢
  • 價格設定及回本環境
  • 生物相似藥的發展
  • SWOT分析

第5章 全球乾癬治療藥市場:開發平台

  • 開發平台概要
  • 有前途的候補藥的開發平台

第6章 企業簡介

  • AbbVie Inc.
  • Amgen, Inc.
  • Johnson & Johnson
  • Novartis AG
  • Eli Lilly and Company
  • AstraZeneca
  • Celgene Corporation
  • UCB
  • Merck

第7章 市場預測

  • 市場未來展望
  • 勝者和敗者
  • 新興企業
  • 未來預測

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GVR-1-68038-662-2

The global psoriasis drugs market size is expected to be valued at USD 21.11 billion by 2022, as per a new report by Grand View Research, Inc., experiencing a CAGR of 9.4% during the forecast period. Rising disease awareness, increasing number of reimbursement strategies for biologics, and advanced diagnostic and technological tools are likely to increase the adoption of psoriasis therapeutics.

Additionally, expanding base of patients suffering from psoriasis is anticipated to fuel growth prospects. The exact causative factors for psoriasis are undetermined; however, certain genetic and environmental factors may trigger the disease onset. Most available treatments aim to decelerate disease progression by stopping hyperproliferation of keratinocyte.

Psoriasis can be classified into five types: plaque, guttate, inverse, pustular, and erythrodermic. The types vary in terms of site of disease and characterization of lesions. Erythrodermic psoriasis is the rarest and plaque psoriasis is the most prevalent type affecting patients all over the world.

Incidence rate of psoriasis has witnessed a gradual rise over the years across various geographical locations. This increase can be attributed to genetic and environmental triggers as well as lifestyle changes. Rise in prevalence rates could also be associated with declining response or developing resistance to therapies for disease control.

Further key findings from the report suggest:

Tumor Necrosis Factor-inhibitors dominated the market in 2016 owing to its higher usage by healthcare practitioners and easy availability

TNF-inhibitors are likely to lose market shares over the forecast period due to increasing preference for IL-inhibitor therapy to conventional TNF-inhibitors

Interleukin-inhibitors is expected to register a lucrative CAGR of over 21.0% during the forecast period owing to improved safety and efficacy profiles of Interleukin-inhibiting drugs

The U.S is the dominant region in the psoriasis market in terms of revenue in 2016 due to increasing number of patients seeking treatment and presence of well-established healthcare services

Japan is expected to be the fastest growing region during the same period due to growing awareness about the disease among the populace

Some of the key players in this industry are: AbbVie Inc.; Amgen Inc.; Johnson & Johnson; Novartis AG; Eli Lilly & Company; AstraZeneca; Celgene Corporation; UCB; and Merck.

Table of Contents

Chapter 1 Research Methodology

  • 1.1 Information Procurement
  • 1.2 Information or Data Analysis
    • 1.2.1 Market Formulation & Validation

Chapter 2 Executive Summary

Chapter 3 Disease Primer and Epidemiology

  • 3.1 Disease Primer
    • 3.1.1 Types:
      • 3.1.1.1 Plaque Psoriasis
      • 3.1.1.2 Guttate Psoriasis
      • 3.1.1.3 Inverse Psoriasis
      • 3.1.1.4 Pustular Psoriasis
      • 3.1.1.5 Erythrodermic Psoriasis
    • 3.1.2 Complications
  • 3.2 Epidemiology by Indications
  • 3.3 Current Prevalence for Seven Major Markets (U.S., Japan, EU5)
  • 3.4 Current Incidence for Seven Major Markets (U.S., Japan, EU5)
  • 3.5 Forecast Prevalence and Incidence (U.S., Japan, EU5)

Chapter 4 Global Psoriasis Drugs Market Overview

  • 4.1 Introduction and Market Overview
    • 4.1.1 Market by Therapeutic Class
      • 4.1.1.1 Tumour Necrosis Factor Inhibitors
      • 4.1.1.1.1 Adalimumab
      • 4.1.1.1.2 Infliximab
      • 4.1.1.1.3 Etanercept
      • 4.1.1.2 InterleU.K.in-Inhibitors
      • 4.1.1.2.1 Ustekinumab
      • 4.1.1.2.2 SecU.K.inumab
      • 4.1.1.2.3 Ixekizumab
      • 4.1.1.2.4 Brodalumab
      • 4.1.1.3 Vitamin D analogues
      • 4.1.1.3.1 Calcitriol
      • 4.1.1.3.2 Calcipotriol
      • 4.1.1.3.3 Tacalcitol
    • 4.1.2 Market by Treatment
      • 4.1.2.1 Topicals
      • 4.1.2.1.1 Over-the-counter (OTC) Topicals
      • 4.1.2.1.2 Topical non-steroids
      • 4.1.2.1.3 Topical Steroids
      • 4.1.2.2 Systemic
      • 4.1.2.2.1 Retinoid
      • 4.1.2.2.2 Cyclosporine
      • 4.1.2.2.3 Methotrexate
      • 4.1.2.3 Biologics
      • 4.1.2.3.1 Tumour necrosis factor alpha (TNF-α) inhibitors
      • 4.1.2.3.2 InterleU.K.in 12 and 23 (IL-12/23) inhibitors
      • 4.1.2.3.3 InterleU.K.in 17 (IL-17) inhibitor
      • 4.1.2.3.4 T cell inhibitor
    • 4.1.3 Market Size & Forecast
    • 4.1.4 Sales Performance
    • 4.1.5 Market Share Distribution
    • 4.1.6 Market Dynamics among Leading Brands
  • 4.2 Patent Expiry Schedule
  • 4.3 Drivers and Challenges
  • 4.4 Deals Landscape (2013-2017)
  • 4.5 Pricing and Reimbursement Environment
  • 4.6 Biosimilar Evolution
    • 4.6.1 India
    • 4.6.2 China
    • 4.6.3 South Korea
  • 4.7 SWOT Analysis

Chapter 5 Global Psoriasis Drugs Market: Pipeline Intelligence

  • 5.1 Pipeline Landscape
    • 5.1.1 Leading Drugs under Development
    • 5.1.2 Key R&D Trends
  • 5.2 Promising Drug Candidates in Pipeline
    • 5.2.1 Late Stage Pipeline and Forecast
    • 5.2.2 Profile of Disruptive Drugs
      • 5.2.2.1 Risankizumab
      • 5.2.2.2 Bimekizumab

Chapter 6 Company Profiles

  • 6.1 AbbVie Inc.
    • 6.1.1 Company Overview
    • 6.1.2 Current Product Portfolio
    • 6.1.3 Product Forecast Sales up to 2022
    • 6.1.4 Strategic Initiatives(Humira)
    • 6.1.5 Company - Key News Flow
    • 6.1.6 Pipeline View
    • 6.1.7 Pipeline Forecast
    • 6.1.8 Catalysts and Event Calendar
    • 6.1.9 SWOT Analysis
  • 6.2 Amgen, Inc.
    • 6.2.1 Company Overview
    • 6.2.2 Current Product Portfolio
    • 6.2.3 Product Forecast Sales up to 2022
    • 6.2.4 Strategic Initiatives(Enbrel)
    • 6.2.5 Company - Key News Flow
    • 6.2.6 Pipeline View
    • 6.2.7 Pipeline Forecast
    • 6.2.8 Catalysts and Event Calendar
    • 6.2.9 SWOT Analysis
  • 6.3 Johnson & Johnson
    • 6.3.1 Company Overview
    • 6.3.2 Current Product Portfolio
    • 6.3.3 Product Forecast Sales up to 2022
    • 6.3.4 Strategic Initiatives
      • 6.3.4.1 Remicade
      • 6.3.4.2 Stelara
      • 6.3.4.3 Tremfya
    • 6.3.5 Company - Key News Flow
    • 6.3.6 Pipeline Forecast
    • 6.3.7 Catalysts and Event Calendar
    • 6.3.8 SWOT Analysis
  • 6.4 Novartis AG
    • 6.4.1 Company Overview
    • 6.4.2 Current Product Portfolio
    • 6.4.3 Product Forecast Sales up to 2022
    • 6.4.4 Strategic Initiatives(Cosentyx)
    • 6.4.5 Company - Key News Flow
    • 6.4.6 Pipeline View
    • 6.4.7 Pipeline Forecast
    • 6.4.8 Catalysts and Event Calendar
    • 6.4.9 SWOT Analysis
  • 6.5 Eli Lilly and Company
    • 6.5.1 Company Overview
    • 6.5.2 Current Product Portfolio
    • 6.5.3 Product Forecast Sales up to 2022
    • 6.5.4 Strategic initiatives(Taltz)
    • 6.5.5 Company - Key News Flow
    • 6.5.6 Pipeline View
    • 6.5.7 Pipeline Forecast
    • 6.5.8 Catalysts and Event Calendar
    • 6.5.9 SWOT Analysis
  • 6.6 AstraZeneca
    • 6.6.1 Company overview
    • 6.6.2 Current Product Portfolio
    • 6.6.3 Product Forecast Sales up to 2022
    • 6.6.4 Strategic Initiatives(Siliq)
    • 6.6.5 Company - Key News Flow
    • 6.6.6 SWOT Analysis
  • 6.7 Celgene Corporation
    • 6.7.1 Company Overview
    • 6.7.2 Current Product Portfolio
    • 6.7.3 Product Forecast Sales up to 2022
    • 6.7.4 Strategic Initiatives(Otezla)
    • 6.7.5 Company - Key News Flow
    • 6.7.6 Pipeline View
    • 6.7.7 Pipeline Forecast
    • 6.7.8 Catalysts and Event Calendar
    • 6.7.9 SWOT Analysis
  • 6.8 UCB
    • 6.8.1 Company Overview
    • 6.8.2 Current Product Portfolio
    • 6.8.3 Product Forecast Sales up to 2022
    • 6.8.4 Strategic Initiatives(Cimzia)
    • 6.8.5 Company - Key News Flow
    • 6.8.6 Pipeline View
    • 6.8.7 Pipeline Forecast
    • 6.8.8 Catalysts and Event Calendar
    • 6.8.9 SWOT Analysis
  • 6.9 Merck
    • 6.9.1 Company Overview
    • 6.9.2 Current Product Portfolio
    • 6.9.3 Product Forecast Sales up to 2022
    • 6.9.4 Strategic Initiatives(Ilumya)
    • 6.9.5 Company - Key News Flow
    • 6.9.6 Pipeline View
    • 6.9.7 Pipeline Forecast
    • 6.9.8 Catalysts and Event Calendar
    • 6.9.9 SWOT Analysis

Chapter 7 Market Outlook

  • 7.1 What the Future Holds
  • 7.2 Winners and Losers
  • 7.3 Emerging Companies
  • 7.4 The Road Ahead

List of Tables

  • TABLE 1 Current Prevalence Across Seven Major Markets - 2016
  • TABLE 2 Current Incidence Across Seven Major Markets - 2016
  • TABLE 3 Forecast Global Prevalence 2016 - 2022
  • TABLE 4 Forecast Global Incidence 2016 - 2022
  • TABLE 5 Forecast Prevalence for Seven Major Markets 2016 - 2022
  • TABLE 6 Forecast Incidence for Seven Major Markets 2016 - 2022
  • TABLE 7 Psoriasis drugs market Size and Forecast (in $million)
  • TABLE 8 Geographic Sales Performance (in $million)
  • TABLE 9 Psoriasis drugs market, by Drug Class (in $million)
  • TABLE 10 Psoriasis Drugs Market Share, by Company (in $million)
  • TABLE 11 Patent Expiry Schedule
  • TABLE 12 Psoriasis Deals Landscape
  • TABLE 13 Psoriasis Drugs under Development
  • TABLE 14 Psoriasis - Late-Stage Pipeline
  • TABLE 15 Global Psoriasis Pipeline Forecast
  • TABLE 16 Product Profile: Risankizumab
  • TABLE 17 Product Profile: Bimekizumab
  • TABLE 18 Product Portfolio: Humira
  • TABLE 19 Humira Forecast Sales up to 2022
  • TABLE 20 AbbVie Pipeline View
  • TABLE 21 AbbVie Catalysts and Event Calendar
  • TABLE 22 Product Portfolio: Enbrel
  • TABLE 23 Enbrel Forecast Sales up to 2022
  • TABLE 24 Amgen Pipeline View
  • TABLE 25 Amgen Catalysts and Event Calendar
  • TABLE 26 Product Portfolio: Remicade
  • TABLE 27 Product Portfolio: Stelara
  • TABLE 28 Product Portfolio: Tremfya
  • TABLE 29 Remicade Forecast Sales up to 2022
  • TABLE 30 Stelara Forecast Sales up to 2022
  • TABLE 31 Tremfya Forecast Sales up to 2022
  • TABLE 32 Johnson & Johnson Pipeline View
  • TABLE 33 Johnson & Johnson Catalysts and Event Calendar
  • TABLE 34 Product Portfolio: Cosentyx
  • TABLE 35 Cosentyx Forecast Sales up to 2022
  • TABLE 36 Novartis Pipeline View
  • TABLE 37 Novartis Catalysts and Event Calendar
  • TABLE 38 Product Portfolio: Taltz
  • TABLE 39 Taltz Forecast Sales up to 2022
  • TABLE 40 Eli Lilly Pipeline View
  • TABLE 41 Eli Lilly Catalysts and Event Calendar
  • TABLE 42 Product Portfolio: Siliq
  • TABLE 43 Siliq Forecast Sales up to 2022
  • TABLE 44 Product Portfolio: Otezla
  • TABLE 45 Otezla Forecast Sales up to 2022
  • TABLE 46 Celgene Pipeline View
  • TABLE 47 Celgene Catalysts and Event Calenadar
  • TABLE 48 Product Portfolio: Cimzia
  • TABLE 49 Cimzia Forecast Sales up to 2022
  • TABLE 50 UCB Pipeline View
  • TABLE 51 UCB Catalysts and Event Calenadar
  • TABLE 52 Product Portfolio: Ilumya
  • TABLE 53 Ilumya Forecast Sales up to 2022
  • TABLE 54 Merck Pipeline View
  • TABLE 55 Merck Catalysts and Event Calenadar

List of Figures

  • FIG. 1 Market Research Process
  • FIG. 2 Information Procurement
  • FIG. 3 Primary research pattern
  • FIG. 4 Market Research Approaches
  • FIG. 5 Value Chain Based Sizing & Forecasting
  • FIG. 6 QFD Modelling for Market Share Assessment
  • FIG. 7 Current Prevalence Across Seven Major Markets - 2016
  • FIG. 8 Current Incidence Across Seven Major Markets - 2016
  • FIG. 9 Global Psoriasis Epidemiology 2016 - 2022
  • FIG. 10 Market segmentation & scope
  • FIG. 11 Psoriasis drugs market, by Country :Forecast 2016 - 2022
  • FIG. 12 Psoriasis drugs market, by Therapeutic class: Forecast 2016 - 2022
  • FIG. 13 Psoriasis drugs market, by Treatment :Forecast 2016 - 2022 (in $million)
  • FIG. 14 Psoriasis Market, by Treatment :Topical Forecast 2016 - 2022 (in million)
  • FIG. 15 Psoriasis Market, by Treatment :Systemic Forecast 2016 - 2022 (in million)
  • FIG. 16 Psoriasis Market, by Treatment : Biologics Forecast 2016 - 2022 (in million)
  • FIG. 17 U.S. Psoriasis Market, by Treatment : Forecast 2016 - 2022 (in $million)
  • FIG. 18 U.S. Psoriasis Market, by Therapeutic class : Forecast 2016 - 2022 (in $million)
  • FIG. 19 EU5 Psoriasis Market, by Treatment : Forecast 2016 - 2022 (in $million)
  • FIG. 20 EU5 Psoriasis Market, by Therapeutic class : Forecast 2016 - 2022 (in $million)
  • FIG. 21 Japan Psoriasis Market, by Treatment : Forecast 2016 - 2022 (in $million)
  • FIG. 22 Japan Psoriasis Market, by Therapeutic class : Forecast 2016 - 2022 (in $million)
  • FIG. 23 Psoriasis Market Share, by Company 2016A-2022E
  • FIG. 24 Market Trends & Outlook
  • FIG. 25 Market Driver Relevance Analysis (Current & future impact)
  • FIG. 26 Market Restraint Relevance Analysis (Current & future impact)
  • FIG. 27 SWOT Analysis (Psoriasis Therapeutic Sector)
  • FIG. 28 Psoriasis Pipeline Assets
  • FIG. 29 SWOT Analysis (AbbVie)
  • FIG. 30 SWOT Analysis (Amgen)
  • FIG. 31 SWOT Analysis (Johnson & Johnson)
  • FIG. 32 SWOT Analysis (Novartis)
  • FIG. 33 SWOT Analysis (Eli Lilly)
  • FIG. 34 SWOT Analysis (AstraZeneca)
  • FIG. 35 SWOT Analysis (Celgene)
  • FIG. 36 SWOT Analysis (UCB)
  • FIG. 37 SWOT Analysis (Merck)
Back to Top